{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "Cognitive impairment",
      "Coronavirus",
      "Dementia",
      "Mild cognitive impairment",
      "Pandemic",
      "SARS-CoV-2"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34556131",
  "DateCompleted": {
    "Year": "2021",
    "Month": "10",
    "Day": "06"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "10",
    "Day": "06"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "09",
        "Day": "23"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "67",
      "10.1186/s13024-021-00492-x"
    ],
    "Journal": {
      "ISSN": "1750-1326",
      "JournalIssue": {
        "Volume": "16",
        "Issue": "1",
        "PubDate": {
          "Year": "2021",
          "Month": "Sep",
          "Day": "23"
        }
      },
      "Title": "Molecular neurodegeneration",
      "ISOAbbreviation": "Mol Neurodegener"
    },
    "ArticleTitle": "Measuring the cognitive costs of the COVID-19 pandemic.",
    "Pagination": {
      "StartPage": "67",
      "MedlinePgn": "67"
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0001-5133-5538"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Neurology, Mayo Clinic in Florida, Jacksonville, Florida, USA. day.gregory@mayo.edu."
          }
        ],
        "LastName": "Day",
        "ForeName": "Gregory S",
        "Initials": "GS"
      }
    ],
    "GrantList": [
      {
        "GrantID": "K23AG064029",
        "Acronym": "AG",
        "Agency": "NIA NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Letter",
      "Research Support, N.I.H., Extramural"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Mol Neurodegener",
    "NlmUniqueID": "101266600",
    "ISSNLinking": "1750-1326"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Cognition"
    },
    {
      "QualifierName": [
        "etiology"
      ],
      "DescriptorName": "Cognitive Dysfunction"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ],
  "CoiStatement": "He owns stock (>$10,000) in ANI Pharmaceuticals (a generic pharmaceutical company). He serves as a topic editor for DynaMed (EBSCO), overseeing development of evidence-based educational content, a consultant for Parabon Nanolabs (advice relevant to NIH small business grant submission), and as the Clinical Director of the Anti-NMDA Receptor Encephalitis Foundation, Inc, Canada (uncompensated)."
}